Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

HIV / AIDS

Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA

HIV Med.

Mills AM, Schulman KL, Fusco JS, Brunet L, Hsu R, Beyer A, Prajapati G, Mounzer K, Fusco GP

doi: 10.1111/hiv.12826.

HIV / AIDS

Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate

Clin Infect Dis.

Dietrich LG, Barceló C, Thorball CW, Ryom L, Burkhalter F, Hasse B, Furrer H, Weisser M, Steffen A, Bernasconi E, Cavassini M, de Seigneux S, Csajka C, Fellay J, Ledergerber B, Tarr PE, Swiss HIV CohortS Study

doi: 10.1093/cid/ciz280.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Hepatology.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S

doi: 10.1002/hep.29642.

HIV / AIDS

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Clin Infect Dis.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

doi: 10.1093/cid/ciy913.

Viral Infections, Non-HIV

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

J Viral Hepat.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt , Negro F

doi: 10.1111/jvh.12891.

Viral Infections, Non-HIV

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Lancet Infect Dis.

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ

doi: 10.1016/

HIV / AIDS

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

Rivero-Juarez A, Tellez F, Castaño-Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua-García M, Zapata-Lopez A, Collado A, Gómez-Vidal MA, Perez-Stachowski J, Muñoz-Medina L, Fernandez-Fuertes E, Rivero A, Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

doi: 10.1111/hiv.12715.

HIV / AIDS

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

HIV Med.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A, EuroSIDA study group

doi: 10.1111/hiv.12711.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Related content

Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA

Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study